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ABSTRACT
FINDbase (http://www.findbase.org) is a comprehen-
sive data repository that records the prevalence of
clinically relevant genomic variants in various popu-
lations worldwide, such as pathogenic variants lead-
ing mostly to monogenic disorders and pharmacoge-
nomics biomarkers. The database also records the
incidence of rare genetic diseases in various popu-
lations, all in well-distinct data modules. Here, we
report extensive data content updates in all data
modules, with direct implications to clinical phar-
macogenomics. Also, we report significant new de-
velopments in FINDbase, namely (i) the release of
a new version of the ETHNOS software that cat-
alyzes development curation of national/ethnic ge-
netic databases, (ii) the migration of all FINDbase
data content into 90 distinct national/ethnic mutation
databases, all built around Microsoft’s PivotViewer
(http://www.getpivot.com) software (iii) new data vi-
sualization tools and (iv) the interrelation of FIND-
base with DruGeVar database with direct implica-
tions in clinical pharmacogenomics. The abovemen-
tioned updates further enhance the impact of FIND-
base, as a key resource for Genomic Medicine appli-
cations.
INTRODUCTION
National and Ethnic Genomic Databases (NEGDBs), pre-
viously known as National and EthnicMutation Databases
or NEMDBs, comprise a well-defined niche of genomic
databases, aiming to record the prevalence of alleles, mainly
pathogenic and of clinical relevance, but also benign, in dif-
ferent populations and ethnic groups worldwide in a struc-
tured manner (1). These resources can be used not only in
population genetic studies, e.g. to study gene/mutation flow
and admixture patterns, human demographic history but
also, and most importantly, in Genomic Medicine, e.g. to
stratify national molecular diagnostic services or to ratio-
nalize drug use (1). NEGDBs can nicely complement the
data content of either central (or core) databases, such as
ClinVar (2) or HGMD (3) and/or locus-specific databases
in general (4).
The first NEGDBswere realized in a very primitive struc-
ture back in 2003, mainly to serve individual populations
and ethnic groups. Couple of years later, and in an ef-
fort to maintain a homogeneous data content, a dedicated
software (ETHNOS; 5) was developed, allowing the de-
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Table 1. Summary of FINDbase worldwide database records (assessed August 2016) within all populations. Average: Average record count per population
within each continent group
Continents Populations Records Average
Africa 15 791 52.73
Americas 5 565 113.00
Asia 30 2574 85.80
Europe 37 4564 123.35
Oceania 3 94 31.33
TOTAL 90 8588 95.42
velopment and curation of NEGDB. In 2006, our group
established FINDbase (Frequency of INherited Disorders
database; http://www.findbase.org), a worldwide database
with the vision to comprehensively document the preva-
lence of clinically relevant genomic variation allele frequen-
cies in various populations and ethnic groupsworldwide (6).
FINDbase contains data only in an aggregated manner, i.e.
allele frequencies stripped from any sensitive personal infor-
mation of their carriers, in order to maintain anonymity (6).
At the beginning, FINDbase accommodated data pertain-
ing to the prevalence of pathogenic genomic variants, e.g.
leading to monogenic disorders (6). Since 2010, FINDbase
also includes prevalence data of pharmacogenomic (PGx)
biomarkers (7) and since 2013, information about the var-
ious rare genetic diseases that are documented in various
populations (8), all in distinct data modules. Content-wise,
FINDbase is the richest database among all NEGDBs cur-
rently available and, it is considered to be one of the key re-
sources to retrieve population-specific information for clin-
ically relevant genomic variations, as indicated by the num-
ber and origin of visitors.
In this paper, we present data content updates in all three
data modules and significant technological advances which
substantially expand the existing data content and visual-
ization tools, so that FINDbase becomes more appealing
to the clinical, apart from the research community.
DATA CONTENT UPDATES
Contrary to the previous FINDbase data content updates
in 2010 (9) and 2013 (10), the recent (2014–2016) update
did not only include data curation, update and correction,
where necessary, but also extensive data enrichment in all
three data modules.
In particular, FINDbase data collection was enriched
with causative genomic variants allele frequencies as far as
the GJB2 and ATP7B genes are concerned, leading to non-
syndromic sensorineural deafness and Wilson disease, re-
spectively. As previously, all entries, representing 930 new
records from 44 populations, were manually curated from
the published literature and entered into the main FIND-
base data collection, recorded against their corresponding
unique PubMed ID.
Also, special attention was given to the data module doc-
umenting PGx marker allele frequencies, which was sig-
nificantly enriched with the prevalence of 36 clinically ac-
tionable PGx biomarkers in 21, mostly European, popula-
tions, resulting from a large multicenter study mapping the
prevalence of PGx biomarkers in Europe (11). Data enrich-
ment was based on the contributor’s unique ResearcherID
(http://www.researcherid.com) and follows the microattri-
bution approach (12), allowing unambiguous identification
of curated data when data update or correction is needed
and, at the same time, providing incentives to potential data
contributors to share their data with the broader scientific
community.
This particular data update is of clinical relevance, as
it allows clinicians to assess whether a particular PGx
biomarker, related with a certain drug’s efficacy or toxic-
ity, is rather prevalent in the population of interest, prior to
prescribing a PGx testing to individualize drug treatment.
FINDbase data compilation and representation are subject
to copyright and usage principles to ensure that FINDbase
and its contents remains freely available to all interested par-
ties.
UPGRADE OF THE ETHNOS SOFTWARE
In the last FINDbase update, we have built a new mod-
ule for rare genetic disease summaries (10), in which we
migrated all genetic disease summary data collection from
five previously developed NEGDBs (Hellenic, Lebanese,
Cypriot, Egyptian and Moroccan). Based on this function-
ality, and given that the component services of all three
modules homogeneously follow the Service Oriented Ar-
chitecture (SOA; 13) and are built around the same data
visualization tool (PivotViewer; http://www.microsoft.com/
silverlight/pivotviewer), we have decided to (i) completely
restructure and upgrade the previous version of the ETH-
NOS software (2), to include improved data submission,
querying and curation functionalities, standing as an ‘off-
the-shelf ’ web application that would allow the develop-
ment of new NEGDBs, (ii) exploit the entire FINDbase
data content, subdivided into 3 modules, to migrate the
entire FINDbase data collection to establish 90 individ-
ual ETHNOS-based NEGDBs in all 5 continents (Ta-
ble 1). These databases are displayed in FINDbase home
page and clustered together according to continent (ETH-
NOS Databases tab; Supplementary Figure S1). Resulting
databases can be subsequently allocated to research groups
and/or consortia in different countries for further data en-
richment with published and unpublished data and expert
data curation, always based on the microattribution ap-
proach (12,14). The upgraded ETHNOS software was used
by the SERBORDISInn Consortium (www.serbordisinn.
rs) to establish the SerbianNEGDB (Supplementary Figure
S2A). In this case, the user can query the clinically relevant
genomic variation allele frequency data and rare genetic dis-
ease summaries only for the Serbian population (Supple-
mentary Figure S2B).
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Figure 1. Integration of DruGeVar with the PGx markers data module of FINDbase. (A) Bar chart showing the number of the related PGx biomarkers
to drugs and the number of related drugs by population sorted by the number of related PGx biomarkers to drugs. The subchart is used for selecting
specific region of the bar chart. (B) Collapsible tree diagram showing the relation between population, PGx biomarkers and drugs. The number between
population and PGx biomarker defines the rare allele frequency and the label between PGx number and drug the effect on the toxicity or efficacy of the
biomarker to the related drug. Clicking on the nodes of PGx biomarkers or drugs additional information for the selected element is appearing in a pop up
window. (C) Pop up window showing additional information for the selected PGx biomarker. Left: Details for the selected PGx marker. Right: Sunburst
visualization, showing the related additional PGx markers and drugs of the gene of the selected PGx biomarker. Clicking on the elements of the PGx
biomarkers, the visualization is reconstructed focusing on the children nodes (related drugs) of the selected node, while clicking on the elements of the
drugs, the visualization is reconstructed focusing on the ‘children’ of the parent node.
The upgraded ETHNOS software complies with the
established recommendations and guidelines to develop
nation-wide projects to document the genetic heterogeneity
in various countries (7).
NEW FEATURES
Apart from the comprehensive data content curation and
update described in the previous paragraphs, we have also
incorporated new features into FINDbase, mostly of clin-
ical relevance. These include the display of the FINDbase
content in a map format, giving a visual first impression of
FINDbase data content spanning across all three datamod-
ules and the interrelation of the PGx module of FINDbase
with DruGeVar database, offering new data visualization
and querying functionalities, as described below.
Transition to HTML5
As previously mentioned, the main visualization tool of
FINDbase querying engine is PivotViewer (http://www.
microsoft.com/silverlight/pivotviewer), which is based on
Microsoft Silverlight technology (http://www.silverlight.
net). The latter requires the installation of the Silverlight
plug-in, which, although freeware, in several installations
is either not available or not allowed. For this reason, we
have made a transition of FINDbase to HTML5 technol-
ogy, which allows the user to access the data without the
need of having Silverlight installed in their workstation. Al-
though this transition may minimally affect the processing
speed in case of large data sets, our experience shows that it
is overall advantageous for FINDbase users.
Integration of DruGeVar database with the pharmacoge-
nomics module of FINDbase
To date, a large number of genomic variants have been
correlated with variable drug response and severity of ad-
verse drug reactions (15). From these, only a small frac-
tion of these variants, referred to as PGx biomarkers,
have been approved by regulatory agencies such that over
120 drugs bear PGx information in their labels. How-
ever, although comprehensive drug-gene lists exist online
in both the US Food and Drug Administration (FDA;
www.fda.gov) and the EuropeanMedicines Agency (EMA;
www.ema.europa.eu), information related to the respective
PGx biomarkers is currently missing from such lists (16).
We have previously extracted information from the pub-
lished literature and online resources and developed a com-
prehensive database, namely DruGeVar (http://drugevar.
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genomicmedicinealliance.org; 17), which triangulates drugs
with genes and PGx biomarkers that could serve clinical
PGx. DruGeVar has been developed in such way to be read-
ily applicable as a standalone resource or a plug-in mod-
ule for other databases documenting relevant information.
Given the fact that the PGx biomarker data module of
FINDbase, not only contains the relevant information but
is also built using the same data visualization tool, namely
PivotViewer and understanding the need for deploying in-
teractive and comprehensive visualizations displaying com-
plex and big data structures, exploiting the wealth of infor-
mation in both databases that are ultimately useful for clin-
icians, we integrated DruGeVar and FINDbase databases.
The FINDbase and DruGeVar integration tool can be
accessed from the FINDbase PGx biomarkers module. The
front end environment focuses on the three related compo-
nents of the DruGeVar database, namely drugs, genes, PGx
biomarkers and populations of the FINDbase database in
purpose to highlight the relation between them. The front
end environment was developed using AngularJS frame-
work (https://angularjs.org) and the architecture of the ap-
plication is based on the AngularJS components adding
reusable elements to the application and the ability of the
configuration of the new features. We added five differ-
ent types of visualizations; (i) collapsible tree diagrams, (ii)
sunburst diagrams, (iii) bar charts, (iv) stacked bar charts
and (v) donut charts. The (i) and (ii) were developed us-
ing D3.js (https://d3js.org) and (iii), (iv) and (v) using C3.js
(http://c3js.org). Collapsible tree diagrams are used to pro-
vide interactive visualizations using hierarchical data for-
mat. The root node of each tree defines a population or
a PGx marker and leads to the related data according the
selection of the user. Collapsible tree diagrams, with pop-
ulation as root node (Figure 1A and B), are provided se-
lecting on an interactive world map (not shown), devel-
oped using Datamaps (http://datamaps.github.io) or by a
provided list of countries. Clicking on the related nodes
of the population’s collapsible tree diagram, additional in-
formation for the selected node is provided. Clicking on
the PGx biomarker’s node, linking the selected popula-
tion to the related drugs, a sunburst diagram visualiza-
tion (Figure 1C), using hierarchical data format, is dis-
played, in addition to visualize the relation between PGx
biomarker’s gene, its related PGx biomarkers and drugs.
The selection of a PGx biomarker, in purpose to construct
a collapsible tree diagram with the PGx biomarker as root
node, follows a filtering flow and begins with the selection
of the related gene from a list of the available genes of
the database and continues with the selection of the PGx
biomarker from the related PGx biomarkers’ list accord-
ing the gene’s selection. In that case, the information pro-
vided includes a table, with filtering, ordering and pagina-
tion of the fields of the related drugs (Figure 2A and B)
developed using Smart Table (http://lorenzofox3.github.io/
smart-tablewebsite). Stacked bar charts, donut charts and
bar charts are used to measure the relation between the ba-
sic components; the percentage of the related PGx biomark-
ers, the number of related PGx biomarkers to drugs and the
number of the related drugs by population.
Establishing the minimumNEGDB information specification
with VarioML
As of early 2007, immediately after its first launch, FIND-
base established synergies with other related genomic
databases (Human Gene Mutation Database (HGMD);
http://www.hgmd.org; 3), or resources (Cafe´ Variome (http:
//www.cafevariome.org); 10).
In 2012, VarioML was developed within the scope of
the GEN2PHEN project framework (www.gen2phen.org),
as a set of tools and practices improving the availability,
quality and comprehensibility of human variation infor-
mation (18). VarioML enables researchers and diagnostic
laboratories to easily and unambiguously share variant in-
formation, by adapting the variant specification into one’s
own research workflow in a straightforward and a sim-
ple ‘push-button’ manner. In other words, genomic varia-
tion data can be easily captured, federated and exchanged,
while more complex data can be also described. Vari-
oML schema is developed using RelaxNG language (http:
//books.xmlschemata.org/relaxng) and it consist of set of
XML building blocks, which can be used for composing
data exchange implementations for specific use cases. Al-
though the VarioML is implemented using XML technolo-
gies, the usage of the schema is not limited only to XML.
Translation tools have been made for example converting
VarioML elements to JSON format and Java programming
language classes. These open source tools and libraries are
made available on GitHub (https://github.com/VarioML).
We have actively participated with the VarioML devel-
opment and used FINDbase data to propose the mini-
mum information specification for NEGDB data exchange
use cases. The developed specification has necessary ele-
ments for describing population structures, genomic vari-
ants and allele frequencies in an appropriatemanner needed
for NEGDBs. For example, variants can have one or more
frequency elements, each of which can be expressed in one
of three formats: (i) decimal number, expressing frequency
as a floating point value, (ii) number of cases, expressing fre-
quency as a count and/or (iii) categorized value, expressing
frequency as an ontology term, for categorized observations
such as ‘exists’ or ‘less than 100’. Further context for the
populations, variants and frequency values can be provided
by evidence code, protocol id, database cross reference and
comment elements. All VarioML elements can hold nec-
essary attributes for unambiguously linking the elements
into relevant ontologies using for example either URIs or
MIRIAM identifiers (http://www.ebi.ac.uk/miriam). Fur-
ther information and examples of use are available at http:
//www.varioml.org/freq minspec.htm.
The map display visualization tool
FINDbase includes a large data set of several clinically rele-
vant genomic data allele frequencies in over 90 populations
and ethnic groups worldwide. In order to give a visual im-
pression of FINDbase data content and, at the same time,
provide a quick access to the available data per population
and per module, we have built a world map that is readily
available at the Home page (Supplementary Figure S3). The
user can zoom in and out in the map, using the + and – keys
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Figure 2. Integration of DruGeVar with the PGx markers data module of FINDbase. Pop up window showing the related data of the selected PGx
biomarker after filtering, displaying the related drugs to the PGx biomarker and additional information in a (A) tabular format and the related populations
of the selected PGx marker in (B) collapsible tree diagram.
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Figure 3. Overview of the newFINDbasemap display visualization tool. (A) Overview of the documented genetic disease summaries in European countries
(part of North Africa is also shown). By hovering the cursor over Greece, a text box appears providing an overview of the number of disease summaries
documented in FINDbase for the Hellenic population. By clicking on the country, a link appears in the bottom down part of the map (indicated in a red
rectangle). Clicking on the link opens a new browser page, where all the different genetic disease summaries in the (B) Hellenic population appear, where
the user can navigate for further information. (C) Overview of the documented PGx markers in European countries (part of North Africa is also shown).
Again, by clicking on a specific country (e.g. Poland), a link appears in the bottom down part of the map (indicated in a red rectangle), which opens a new
browser page, where all the different PGx markers in the Polish population appear, (D) grouped per gene. Please note that the intensity of the blue color is
indicative of the number of data records that are documented in FINDbase for every country per data module, respectively (see also Supplementary Figure
S4).
and select the data module desired, namely causative muta-
tions, PGx markers or disease summaries from the top left
corner of the map. Alternatively, the user can select the map
display per continent, from the top right corner of the map.
By hovering the cursor over each country, a text box display
provides the exact number or records in this population for
the selected data module, while a visual impression is also
provided with different shades of blue, depending on the to-
tal number of entries per data module (the darker the color
the more data recorded; Figure 3A and C). By clicking on
the left mouse button, a hyperlink appears at the bottom
left side of the map, which directs the user to the data query
page, where all available records for this selection are pro-
vided (Figure 3B and D).
CONCLUSIONS AND FUTURE PERSPECTIVES
FINDbase is a comprehensive online resource document-
ing the prevalence of clinically relevant genomic varia-
tion allele frequency data, serving a well-defined scien-
tific discipline. Ever since its establishment in 2006, it
is considered a reference repository of such information
worldwide. To maximize its utility, access of FINDbase
content is kept free of charge, while both the data con-
tent and the battery of data visualization tools have been
significantly enriched. This was made possible thanks to
the uninterrupted funding of this database since 2005, as
part of major research Consortia, such as GEN2PHEN
(http://www.gen2phen.org), RD-Connect (http://www.rd-
connect.eu) and the Genomic Medicine Alliance (http://
www.genomicmedicinealliance.org), also ensuring fruitful
interactions with the field’s leading experts.
The recent update of FINDbase data modules focused
primarily in the PGx data collection, not only by expanding
the existing data sets with information about the prevalence
of clinically actionable PGx biomarkers in many European
and other populations but, most importantly, by interrelat-
ing the PGx data module with DruGeVar, hence providing
the interested users with the best of both resources. Also,
the upgrade of the ETHNOS software, as an ‘off-the-shelf ’
web application forNEGDBdevelopment and curation, of-
fers a unique opportunity to interested users, with mini-
mal or even no (bio)informatics background, either to start
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a new NEGDB from scratch or even to ‘adopt’ an exist-
ing NEGDB from the FINDbase collection and, together
with a group of expert curators from their own country,
to assume responsibility of enriching it with content, with
all technical support being provided centrally by FIND-
base administrators. This also contributes to harmonized
NEGDB development and minimizes data content hetero-
geneity. Also, the interrelation of DruGeVar and FIND-
base PGx module can catalyze the efforts of national reg-
ulatory agencies to develop guidelines to rationalize drug
use in those populations, where certain clinically actionable
PGx biomarkers reach high frequencies.
To accommodate the anticipated increased data gener-
ation, especially from next-generation sequencing (NGS)
and microarray experiments, FINDbase architecture will
have to be further modernized. In particular, we do not
only plan to design a system for microarray (e.g. for the
Affymetrix DMETTM Plus platform) or NGS data upload-
ing, but also to improvise an algorithm to automatically
calculate clinically relevant genomic variants in an aggre-
gated manner to ensure data anonymity. Such increase in
data coverage would require upgraded data visualization
tools, using a variety of techniques, such as the drill-down
approach.
These data will be contributed with microattribution,
supporting additional forms of contributor identification
apart from the ResearcherID (e.g. ORCID; http://www.
orcid.org), and flagged with a certain label (e.g. mA), and
deposited using DOI and/or PubMed ID, hence providing
minimal credit to data contributors and curators. Such data
are already available for testing as far as PGx biomarkers
(11) and pharmacogenes (11,19) are concerned.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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